The effects of orally ingested Delta-9-Tetrahydrocannabinol on drivers' hazard perception and risk-taking behaviours: A within-subjects study of medicinal cannabis users.

IF 3.3 3区 医学 Q2 NEUROSCIENCES
Taren Mieran, Andrew Hill, Mark S Horswill, Mathew J Summers, Kayla B Stefanidis
{"title":"The effects of orally ingested Delta-9-Tetrahydrocannabinol on drivers' hazard perception and risk-taking behaviours: A within-subjects study of medicinal cannabis users.","authors":"Taren Mieran, Andrew Hill, Mark S Horswill, Mathew J Summers, Kayla B Stefanidis","doi":"10.1007/s00213-025-06869-w","DOIUrl":null,"url":null,"abstract":"<p><p>Medicinal cannabis use is increasing worldwide, yet its impacts on driving safety in frequent users are not clearly understood. A more comprehensive understanding of the effects of THC on driving behaviour in frequent users is needed to guide drug driving policy and evidence-based advice for medicinal cannabis consumers. This study investigated the acute effects of orally ingested THC oil on medicinal cannabis users': (a) hazard perception skill performance; (b) driving-related risk-taking behaviours (speeding propensity, following distance, gap acceptance); (c) self-perceived hazard perception skill performance; and (d) self-perceptions of driving skills and safety. A within-subjects design was used to compare scores on validated video-based measures of hazard perception skill and risk-taking behaviours, along with self-report measures, between baseline (no THC) and post-consumption. Although participants' (N = 41) actual hazard perception skill performance did not significantly decline from baseline to post-consumption, their perceived performance did (with no significant correlation between the two in either condition). In the other video-based measures, participants selected significantly slower speeds and longer following distances post-consumption (but gap acceptance behaviour was unchanged). There was no significant change in self-perceptions of driving skills and safety after correction for multiple tests. While there was no evidence that oral ingestion of THC oils by medicinal cannabis users impacted hazard perception skill performance, they were unable to accurately self-assess their performance, regardless of whether they had consumed THC. Further, medicinal cannabis patients engage in compensatory strategies, specifically by reducing their speed and increasing their following distance following the consumption of THC.</p>","PeriodicalId":20783,"journal":{"name":"Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00213-025-06869-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Medicinal cannabis use is increasing worldwide, yet its impacts on driving safety in frequent users are not clearly understood. A more comprehensive understanding of the effects of THC on driving behaviour in frequent users is needed to guide drug driving policy and evidence-based advice for medicinal cannabis consumers. This study investigated the acute effects of orally ingested THC oil on medicinal cannabis users': (a) hazard perception skill performance; (b) driving-related risk-taking behaviours (speeding propensity, following distance, gap acceptance); (c) self-perceived hazard perception skill performance; and (d) self-perceptions of driving skills and safety. A within-subjects design was used to compare scores on validated video-based measures of hazard perception skill and risk-taking behaviours, along with self-report measures, between baseline (no THC) and post-consumption. Although participants' (N = 41) actual hazard perception skill performance did not significantly decline from baseline to post-consumption, their perceived performance did (with no significant correlation between the two in either condition). In the other video-based measures, participants selected significantly slower speeds and longer following distances post-consumption (but gap acceptance behaviour was unchanged). There was no significant change in self-perceptions of driving skills and safety after correction for multiple tests. While there was no evidence that oral ingestion of THC oils by medicinal cannabis users impacted hazard perception skill performance, they were unable to accurately self-assess their performance, regardless of whether they had consumed THC. Further, medicinal cannabis patients engage in compensatory strategies, specifically by reducing their speed and increasing their following distance following the consumption of THC.

口服德尔塔-9-四氢大麻酚对驾驶员危险感知和冒险行为的影响:一项对医用大麻使用者的受试者内研究。
医用大麻的使用在世界范围内不断增加,但其对频繁使用者驾驶安全的影响尚不清楚。需要更全面地了解四氢大麻酚对频繁使用者驾驶行为的影响,以指导药物驾驶政策并为医用大麻消费者提供循证咨询。本研究调查了口服四氢大麻酚油对药用大麻使用者的急性影响:(a)危害感知技能表现;(b)与驾驶有关的冒险行为(超速倾向、跟随距离、间隙接受);(c)自我感知危险感知技能表现;(d)对驾驶技术和安全的自我认知。受试者内设计用于比较基线(无四氢大麻酚)和消费后的危险感知技能和冒险行为的有效视频测量以及自我报告测量的分数。虽然参与者(N = 41)的实际危险感知技能表现从基线到消费后并没有显著下降,但他们的感知表现却有所下降(在两种情况下两者之间都没有显著的相关性)。在其他基于视频的测量中,参与者在消费后选择了明显较慢的速度和较长的跟随距离(但间隙接受行为没有改变)。经多次测试校正后,对驾驶技术和安全的自我认知无明显变化。虽然没有证据表明药用大麻使用者口服四氢大麻酚油会影响危害感知技能的表现,但无论他们是否服用四氢大麻酚,他们都无法准确地自我评估自己的表现。此外,药用大麻患者参与代偿策略,特别是通过降低其速度和增加四氢大麻酚消费后的跟随距离。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Psychopharmacology
Psychopharmacology 医学-精神病学
CiteScore
7.10
自引率
5.90%
发文量
257
审稿时长
2-4 weeks
期刊介绍: Official Journal of the European Behavioural Pharmacology Society (EBPS) Psychopharmacology is an international journal that covers the broad topic of elucidating mechanisms by which drugs affect behavior. The scope of the journal encompasses the following fields: Human Psychopharmacology: Experimental This section includes manuscripts describing the effects of drugs on mood, behavior, cognition and physiology in humans. The journal encourages submissions that involve brain imaging, genetics, neuroendocrinology, and developmental topics. Usually manuscripts in this section describe studies conducted under controlled conditions, but occasionally descriptive or observational studies are also considered. Human Psychopharmacology: Clinical and Translational This section comprises studies addressing the broad intersection of drugs and psychiatric illness. This includes not only clinical trials and studies of drug usage and metabolism, drug surveillance, and pharmacoepidemiology, but also work utilizing the entire range of clinically relevant methodologies, including neuroimaging, pharmacogenetics, cognitive science, biomarkers, and others. Work directed toward the translation of preclinical to clinical knowledge is especially encouraged. The key feature of submissions to this section is that they involve a focus on clinical aspects. Preclinical psychopharmacology: Behavioral and Neural This section considers reports on the effects of compounds with defined chemical structures on any aspect of behavior, in particular when correlated with neurochemical effects, in species other than humans. Manuscripts containing neuroscientific techniques in combination with behavior are welcome. We encourage reports of studies that provide insight into the mechanisms of drug action, at the behavioral and molecular levels. Preclinical Psychopharmacology: Translational This section considers manuscripts that enhance the confidence in a central mechanism that could be of therapeutic value for psychiatric or neurological patients, using disease-relevant preclinical models and tests, or that report on preclinical manipulations and challenges that have the potential to be translated to the clinic. Studies aiming at the refinement of preclinical models based upon clinical findings (back-translation) will also be considered. The journal particularly encourages submissions that integrate measures of target tissue exposure, activity on the molecular target and/or modulation of the targeted biochemical pathways. Preclinical Psychopharmacology: Molecular, Genetic and Epigenetic This section focuses on the molecular and cellular actions of neuropharmacological agents / drugs, and the identification / validation of drug targets affecting the CNS in health and disease. We particularly encourage studies that provide insight into the mechanisms of drug action at the molecular level. Manuscripts containing evidence for genetic or epigenetic effects on neurochemistry or behavior are welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信